{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T05:56:49Z","timestamp":1716530209218},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.ejim.2007.09.004","type":"journal-article","created":{"date-parts":[[2007,12,4]],"date-time":"2007-12-04T15:32:55Z","timestamp":1196782375000},"page":"203-208","source":"Crossref","is-referenced-by-count":4,"title":["Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia"],"prefix":"10.1016","volume":"19","author":[{"given":"Inbal","family":"Avisar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Gerald","family":"Brook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efrat","family":"Wolfovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2007.09.004_bib1","unstructured":"Harrison's Principles of Internal Medicine 16th Ed., vol. 2, p. 2292\u20132293."},{"key":"10.1016\/j.ejim.2007.09.004_bib2","first-page":"2486","volume":"285","year":"2001"},{"key":"10.1016\/j.ejim.2007.09.004_bib3","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2007.09.004_bib4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/clc.4960181107","article-title":"Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia","volume":"18","author":"Bruckert","year":"1995","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ejim.2007.09.004_bib5","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/00007611-199705000-00018","article-title":"Rhabdomyolysis associated with simvastatin\u2013gemfibrozil therapy","volume":"90","author":"Tal","year":"1997","journal-title":"South Med J"},{"key":"10.1016\/j.ejim.2007.09.004_bib6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0002-9149(97)00907-7","article-title":"Rhabdomyolysis after taking atorvastatin with gemfibrozil","volume":"81","author":"Duell","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2007.09.004_bib7","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0002-9149(97)00430-X","article-title":"Safety and efficacy of long-term statin\u2013fibrate combinations in patients with refractory familial combined hyperlipidemia","volume":"80","author":"Athyros","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2007.09.004_bib8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0002-9343(97)00311-2","article-title":"A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group","volume":"104","author":"McKenney","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2007.09.004_bib9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1124\/jpet.105.085522","article-title":"Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes","volume":"315","author":"Bach-Ngohou","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ejim.2007.09.004_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00043798-200202000-00005","article-title":"Atorvastatin versus four statin\u2013fibrate combinations in patients with familial combined hyperlipidemia","volume":"9","author":"Athyros","year":"2002","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.ejim.2007.09.004_bib11","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2005.02.052","article-title":"Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia","volume":"45","author":"Koh","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2007.09.004_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0021-9150(96)06052-2","article-title":"Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia","volume":"130","author":"Bertolini","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2007.09.004_bib13","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.ATV.15.5.678","article-title":"Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor","volume":"15","author":"Nawrocki","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2007.09.004_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/107424849800300204","article-title":"Placebo-controlled, dose-ranging study of atorvastatin","volume":"3","author":"Schrott","year":"1998","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ejim.2007.09.004_bib15","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0002-9149(97)00174-4","article-title":"Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I","volume":"79","author":"Davidson","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2007.09.004_bib16","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0002-9149(00)01430-2","article-title":"Comparison of efficacy and safety of atorvastatin (10\u00a0mg) with simvastatin (10\u00a0mg) at six weeks. ASSET Investigators","volume":"87","author":"Insull","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2007.09.004_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9149(97)00280-4","article-title":"A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia","volume":"80","author":"Dart","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2007.09.004_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/01.ATV.20.1.189","article-title":"Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles","volume":"20","author":"Guerin","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2007.09.004_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0021-9150(97)06066-8","article-title":"A brief review paper of the efficacy and safety of atorvastatin in early clinical trials","volume":"131","author":"Bakker-Arkema","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2007.09.004_bib20","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1161\/01.ATV.17.9.1793","article-title":"Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate","volume":"17","author":"Ooi","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2007.09.004_bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0002-9149(00)01012-2","article-title":"High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia","volume":"86","author":"Wierzbicki","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2007.09.004_bib22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1046\/j.1365-2796.2002.00988.x","article-title":"Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial","volume":"251","author":"Despres","year":"2002","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejim.2007.09.004_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-9149(00)01270-4","article-title":"Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia","volume":"87","author":"Frost","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2007.09.004_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/204748739900600208","article-title":"Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia","volume":"6","author":"Bairaktari","year":"1999","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.ejim.2007.09.004_bib25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/heart.88.3.234","article-title":"Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia","volume":"88","author":"Van Dam","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2007.09.004_bib26","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2007.09.004_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease","volume":"352","author":"Nissen","year":"2005","journal-title":"N Engl J Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620507002634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620507002634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T11:58:03Z","timestamp":1546430283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620507002634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0953620507002634"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2007.09.004","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}